Sera Prognostics, Inc. (SERA)
NGM · Healthcare · Medical Devices
Closing price as of 2026-09-11 · Source: TEK2day Finance
Key Metrics
About Sera Prognostics, Inc.
Sera Prognostics, Inc., a women's health company, discovers, develops, and commercializes blood-based biomarker tests, and predictive analytic products and services in the United States. The company develops the PreTRM test, a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation. It is also involved in the development of a pipeline of novel blood-based biomarker tests and predictive analytic products and services for pregnancy related conditions, such as time-to-birth, predictive analytics product, pregnancy risk prediction panel, preeclampsia, and fetal growth restriction. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.
Quarterly Financials
| Metric | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|
| Revenue | 16K | 10K | 14K | 30K |
| Gross Profit | (25K) | (32K) | (28K) | (20K) |
| Operating Income | (9.0M) | (9.0M) | (9.4M) | (10.0M) |
| Net Income | (7.8M) | (7.9M) | (8.4M) | (9.1M) |
| Diluted EPS | $-0.16 | $-0.16 | $-0.17 | $-0.18 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 268K | 306K | 77K | 81K |
| Gross Profit | 75K | 96K | (5K) | (83K) |
| Operating Income | (45.7M) | (39.8M) | (36.6M) | (36.5M) |
| Net Income | (44.2M) | (36.2M) | (32.9M) | (31.9M) |
| Diluted EPS | $-1.43 | $-1.16 | $-0.99 | $-0.67 |